Bencycloquidium Bromide

苯环喹溴铵

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBencycloquidium Bromide
Drug Alias Name必立汀BCQBYG-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M1 antagonistsMuscarinic acetylcholine receptor M3 antagonists
TargetsMuscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M3
Therapy Area/IndicationsRhinitis, Allergic, PerennialRhinitis, AllergicPulmonary Disease, Chronic Obstructive +[4] 
Global Approved IndicationsRhinitis, Allergic
Approved Indications in ChinaRhinitis, Allergic
Original Approved Country/TerritoryMainland China
Original Approved Date2020/03/17
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Jiashitang Biological Medicine Co LtdBeijing Sciecure Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesState Pharmaceutical Administration of Shanghai Institute of Pharmaceutical IndustryBeijing Jiashitang Biological Medicine Co LtdBeijing Sciecure Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsRhinitis, Allergic, PerennialRhinitis, AllergicPulmonary Disease, Chronic Obstructive +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeR01
Related LinksN/A